Hims & Hers Health, Inc. (HIMS)
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading session.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: The Bull Case Remains Strong
Hims & Hers remains attractive at $33, supported by renewed Novo Nordisk partnership and unique access to patient demand. Despite weak Q1 2026 results—4% revenue growth, declining margins, and a net loss—international expansion and diversified categories are strengthening the long-term outlook. Management targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, with valuation justified if retention and cross-sell improve.
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.89, moving +1.33% from the previous trading session.
Hims & Hers Enters A New Phase
The Novo Nordisk partnership transformed Hims & Hers Health, Inc. from a fringe obesity player into an official healthcare ecosystem participant. Short interest remains elevated near 30%-32% of the HIMS float, leaving roughly 63 million shares vulnerable to further covering. HIMS management targets at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 through platform expansion.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Hims & Hers Health, Inc. (HIMS) closed at $27.71 in the latest trading session, marking a -4.38% move from the prior day.
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Expands Integrated Health Access via Platform Expansion
HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.
HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
Hims & Hers and Tempus AI are taking different paths in AI-driven healthcare, but which stock offers stronger upside now? Let's dive in.
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA
Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America said. Analysts estimate HIMS would need to add approximately 225,000 new oral Wegovy subscribers per quarter from the second through fourth quarters of 2026 to reach the midpoint of its full-year sales guidance.
